Urology Times 50 Innovations Series: PSA testing

Patients who underwent treatment with SBRT demonstrated a 5-year disease control rate of 96%, compared with 95% among patients who underwent conventionally fractionated radiation therapy.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

In the first article of this series, Naveen Kella, MD, discusses the transformative impact of PSMA PET-CT imaging on prostate cancer diagnosis, highlighting its advantages and addressing clinical challenges and guidelines in this evolving field.